Kronos Bio Inc
NASDAQ:KRON
Kronos Bio Inc
NASDAQ:KRON
Price:
1.02 USD
3.89%
Market Closed
Updated:
May 19, 2024
Kronos Bio Inc
Cash from Financing Activities
|
Kronos Bio Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Kronos Bio Inc
NASDAQ:KRON
|
Cash from Financing Activities
$567k
|
CAGR 3-Years
-89%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$211m
|
CAGR 3-Years
74%
|
CAGR 5-Years
59%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$625m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Kronos Bio Inc's Cash from Financing Activities?
Cash from Financing Activities
567k
USD
567k
USD
Based on the financial report for Dec 31, 2023, Kronos Bio Inc's Cash from Financing Activities amounts to 567k USD.
What is Kronos Bio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-49%
-49%
Over the last year, the Cash from Financing Activities growth was -33%. The average annual Cash from Financing Activities growth rates for Kronos Bio Inc have been -89% over the past three years , -49% over the past five years .
You don't have any saved screeners yet
